Tag: ARDS
90 Day Outcomes of COVID-19 Patients in European ICUs
This communication delineates outcomes in COVID-19 patients in the context of ARDS severity, ventilatory management, and variables associated with mortality on a 90-day follow-up for subgroups of patients after ICU admission.... read more
COVID-19: Critical Care and Airway Management Issues
Among patients hospitalized with coronavirus disease 2019 (COVID-19), up to one-quarter require intensive care unit (ICU) admission. Profound hypoxemic respiratory failure from acute respiratory distress syndrome (ARDS)... read more
Prone Position in Intubated, Mechanically Ventilated COVID-19 Patients
During the COVID-19 pandemic, prone position has been widely adopted to treat mechanically ventilated patients with respiratory failure. The majority of patients improved their oxygenation during prone position, most likely... read more
Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients
A new study by Masimo published in Critical Care evaluated the impact of a variety of rescue therapies on the systemic and cerebral oxygenation of mechanically ventilated COVID-19 patients suffering from acute respiratory... read more
NeuroRx Announced Completion of Data Analysis for COVID-19 Treatment Respiratory Failure
NeuroRx, Inc. announced completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill... read more
Cerecor Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in reducing respiratory failure and mortality at Day 28 in patients hospitalized... read more
Efficacy of Serum Angiotensin II Levels in Prognosis of Patients with COVID-19
The serum angiotensin II levels decrease significantly in patients with coronavirus disease 2019, and this decrease is correlated with lung damage. There was no statistical significance between the serum angiotensin II... read more
No Significant Difference between Tocilizumab and Placebo in Severe COVID-19 Pneumonia Patients
In this randomized trial involving hospitalized patients with severe COVID-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. In this... read more
Temporal Changes in the Epidemiology, Management, and Outcome from ARDS
The frequency of and outcome from ARDS remained relatively stable between 2002 and 2012. Plateau pressure > 29 cmH2O and driving pressure > 14 cmH2O on the first day of mechanical ventilation but not tidal volume > 8... read more
Physiological dead space and alveolar ventilation in ventilated infants
Prematurely born infants with pulmonary disease have a higher dead space than term controls, which may influence the optimum level during volume-targeted ventilation. A prospective study of mechanically ventilated infants... read more
Causes and Timing of Death in Critically Ill COVID-19 Patients
Mortality rate of critically ill COVID-19 patients is high, especially in those requiring invasive mechanical ventilation. However, the causes and the timing of death of patients admitted to the ICU for SARS-CoV-2 pneumonia... read more
Insight into ECMO, mortality and ARDS
ARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization... read more
Consequences of COVID-19 in discharged patients
At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay... read more
Nebulised heparin for patients with or at risk of ARDS
In patients with or at risk of acute respiratory distress syndrome (ARDS), nebulised heparin did not improve self-reported performance of daily physical activities, but was well tolerated and exploratory outcomes suggest... read more
Meralgia Paresthetica: COVID-19-associated ARDS treated with prone positioning
Prone positioning is one of the few interventions in acute respiratory distress syndrome (ARDS) which has a proven mortality reduction. Due to the coronavirus disease 2019 (COVID-19) pandemic, severe ARDS cases have sharply... read more
Subtle Presentations of Shock in the ED Setting
The patient was a 2-year-old female with a history of allergy to peanuts who was brought to the emergency department by her mother because of a complaint of allergic reaction. Twenty minutes prior to arrival, the patient... read more
Harnessing a Pioneering Cell Therapy Treatment for COVID-19 Patients with ARF
A world-leading UK-wide trial supported by NIHR is offering a pioneering cell therapy treatment for patients with acute respiratory failure (ARF) caused by COVID-19. The groundbreaking study, led by experts at Queen's... read more
